HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price Target
Belite Bio, Inc. ADR
Belite Bio, Inc. ADR BLTE | 0.00 |
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:
BLTE) with a Buy and maintains $200 price target.
